151 related articles for article (PubMed ID: 2896754)
1. Impact of molecular biology on Pseudomonas aeruginosa immunization.
Pennington JE
J Hosp Infect; 1988 Feb; 11 Suppl A():96-102. PubMed ID: 2896754
[TBL] [Abstract][Full Text] [Related]
2. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
Pennington JE; Pier GB; Sadoff JC; Small GJ
Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa. Vaccines and immunotherapy.
Pennington JE
Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
5. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
[TBL] [Abstract][Full Text] [Related]
6. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.
Pennington JE; Small GJ; Lostrom ME; Pier GB
Infect Immun; 1986 Oct; 54(1):239-44. PubMed ID: 3093385
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
Pennington JE; Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES; Lam JS
FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
[TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.
Zweerink HJ; Gammon MC; Hutchison CF; Jackson JJ; Lombardo D; Miner KM; Puckett JM; Sewell TJ; Sigal NH
Infect Immun; 1988 Aug; 56(8):1873-9. PubMed ID: 3135264
[TBL] [Abstract][Full Text] [Related]
11. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.
Finke M; Muth G; Reichhelm T; Thoma M; Duchêne M; Hungerer KD; Domdey H; von Specht BU
Infect Immun; 1991 Apr; 59(4):1251-4. PubMed ID: 1706316
[TBL] [Abstract][Full Text] [Related]
12. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
[TBL] [Abstract][Full Text] [Related]
14. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans.
Pollack M
J Infect Dis; 1983 Jun; 147(6):1090-8. PubMed ID: 6406615
[TBL] [Abstract][Full Text] [Related]
15. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
16. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa.
Bruderer U; Fürer E; Cryz SJ; Lang AB
Res Immunol; 1992 Feb; 143(2):165-74. PubMed ID: 1374194
[TBL] [Abstract][Full Text] [Related]
17. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode.
Ahmadi TS; Mousavi Gargari SL; Talei D
Mol Immunol; 2021 Aug; 136():118-127. PubMed ID: 34130152
[TBL] [Abstract][Full Text] [Related]
18. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.
Pier GB; Koles NL; Meluleni G; Hatano K; Pollack M
Infect Immun; 1994 Apr; 62(4):1137-43. PubMed ID: 8132318
[TBL] [Abstract][Full Text] [Related]
19. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.
Stoll BJ; Pollack M; Young LS; Koles N; Gascon R; Pier GB
Infect Immun; 1986 Sep; 53(3):656-62. PubMed ID: 2427453
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay.
Eckhardt A; Heiss MM; Ehret W; Permanetter W; Duchêne M; Domdey H; von Specht BU
Zentralbl Bakteriol; 1991 Apr; 275(1):100-11. PubMed ID: 1930557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
